The peripheral apparatus of muscle pain: Evidence from animal and human studies

被引:188
|
作者
Graven-Nielsen, T
Mense, S
机构
[1] Aalborg Univ, Ctr Sensory Motor Interact, Lab Expt Pain Res, DK-9220 Aalborg E, Denmark
[2] Heidelberg Univ, Inst Anat & Zellbiol 3, Heidelberg, Germany
来源
CLINICAL JOURNAL OF PAIN | 2001年 / 17卷 / 01期
关键词
muscle pain; muscle nociception; sensitization; hyperalgesia;
D O I
10.1097/00002508-200103000-00002
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
The peripheral apparatus of muscle pain consists of nociceptors that can be excited by endogenous substances and mechanical stimuli. Histologically, the nociceptors are free nerve endings supplied by group III (thin myelinated) and group IV (nonmyelinated) afferents with conduction velocities less than 30 m/s. At the molecular level, nociceptors have receptors for algesic substances, such as bradykinin, serotonin, and prostagladin E2. The purinergic receptors and tetrodotoxin-resistant sodium channels might be new important targets for the treatment of muscle pain. Algesic substances (capsaicin, bradykinin, serotonin, potassium chloride, and hypertonic saline) and other stimuli (ischemia, strong mechanical stimuli, and electrical stimuli) have been shown to induce nociception from muscle in animals and muscle pain in humans. Muscle nociceptors can be sensitized to chemical and mechanical stimuli. Contrary to a former belief, the sensitization is not an unspecific process; rather, it is caused by endogenous algesic substances binding to highly specific receptor molecules in the membrane of the nociceptive ending. For example, animal studies showed that serotonin sensitizes muscle nociceptors to chemical and mechanical stimuli. Later, human studies showed that serotonin combined with bradykinin induces muscle hyperalgesia to pressure. The sensitization process by endogenous substances that are likely to be released during trauma or inflammatory injury is probably the best established peripheral mechanism for muscle tenderness and hyperalgesia.
引用
收藏
页码:2 / 10
页数:9
相关论文
共 50 条
  • [31] Animal pain and human pain
    Le Bars, D
    MEDICAL RESEARCH AT THE DAWN OF THE 21ST CENTURY: MEDICAL RESEARCH AND ANIMAL MODELS, 2002, : 166 - 173
  • [32] Postoperative Pain Management and Proinflammatory Cytokines: Animal and Human Studies
    Yehuda Shavit
    Keren Fridel
    Benzion Beilin
    Journal of Neuroimmune Pharmacology, 2006, 1 : 443 - 451
  • [33] Postoperative Pain Management and Proinflammatory Cytokines: Animal and Human Studies
    Shavit, Yehuda
    Fridel, Keren
    Beilin, Benzion
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2006, 1 (04) : 443 - 451
  • [34] Brain imaging as a surrogate measure of pain: Human and animal studies
    Bushnell, MC
    Emerging Strategies for the Treatment of Neuropathic Pain, 2006, : 383 - 405
  • [35] Selenium and diabetes - evidence from animal studies
    Lei, X. G.
    FREE RADICAL BIOLOGY AND MEDICINE, 2012, 53 : S19 - S20
  • [36] Opioids in neuropathic pain: clues from animal studies
    Dickenson, AH
    Suzuki, R
    EUROPEAN JOURNAL OF PAIN, 2005, 9 (02) : 113 - 116
  • [37] Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies
    McGuire, Matthew J.
    Ishii, Makoto
    CELLULAR AND MOLECULAR NEUROBIOLOGY, 2016, 36 (02) : 203 - 217
  • [38] Recent evidence from human and animal studies regarding iron status and infant development
    Beard, John
    JOURNAL OF NUTRITION, 2007, 137 (02): : 524S - 530S
  • [39] Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies
    Sabrina F. Lisboa
    C. Vila-Verde
    J. Rosa
    D. L. Uliana
    C. A. J. Stern
    L. J. Bertoglio
    L. B. Resstel
    F. S. Guimaraes
    Psychopharmacology, 2019, 236 : 201 - 226
  • [40] Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies
    Lisboa, Sabrina F.
    Vila-Verde, C.
    Rosa, J.
    Uliana, D. L.
    Stern, C. A. J.
    Bertoglio, L. J.
    Resstel, L. B.
    Guimaraes, F. S.
    PSYCHOPHARMACOLOGY, 2019, 236 (01) : 201 - 226